Novo Nordisk deepens Aspect Biosystems alliance in push for curative diabetes cell therapies

Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies

Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half

The study evaluated patients with stage III/IV melanoma after complete tumor resection

HRV Pharma & SMS LifeSciences form strategic partnership for orphan and niche APIs

FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer

Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells

AGC Biologics powers commercial launch of its life-changing gene therapy for rare childhood immune disorder

Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector

Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future

India in the Changing Landscape of Life-Sciences Research & Development

Kindeva appoints David Stevens as new CEO

Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors

AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial

Improvements were also seen in complete response rates, duration of response, and time to next treatment

IRLAB Therapeutics teams up with Biomia to advance novel CNS drug candidates

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike